Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women

Radiotherapy and Oncology

Volumn 85, Issue 3, 2007, Pages 336-345

  Bollet, Marc A ^a   Kirova, Youlia M ^a   Antoni, Guillemette ^a   Pierga, Jean Yues ^a   Sigal Zafrani, Brigitte ^a   Laki, Fatima ^a   Campana, François ^a   Dendale, Rémi ^a   Salmon, Rémy ^a   Cottu, Paul ^a   Fourquet, Alain ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Concurrent; Hormone therapy; Neoadjuvant; Radiotherapy

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHEDEMA; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 36749000476     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.10.003     Document Type: Article

References (66)

1. Mauriac L., MacGrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 (1999) 47-52
2. Broet P., Scholl S.M., de la Rochefordiere A., et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 58 (1999) 151-156
3. Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr (2001) 96-102
4. Cleator S.J., Makris A., Ashley S.E., Lal R., and Powles T.J. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 16 (2005) 267-272
5. van der Hage J.A., van de Velde C.J., Julien J.P., Tubiana-Hulin M., Vandervelden C., and Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19 (2001) 4224-4237
6. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 (2005) 188-194
7. Remontet L., Esteve J., Bouvier A.M., et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publ 51 (2003) 3-30
8. Colleoni M., Viale G., Zahrieh D., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10 (2004) 6622-6628
9. Ring A.E., Smith I.E., Ashley S., Fulford L.G., and Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91 (2004) 2012-2017
10. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
11. Whelan T.J., Julian J., Wright J., Jadad A.R., and Levine M.L. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18 (2000) 1220-1229
12. Fourquet A., Vilcoq J.R., Zafrani B., Schlienger P., Jullien D., and Campana F. Medullary breast carcinoma: the role of radiotherapy as primary treatment. Radiother Oncol 10 (1987) 1-6
13. Prosnitz L.R., and Goldenberg I.S. Radiation therapy as primary treatment for early stage carcinoma of the breast. Cancer 35 (1975) 1587-1596
14. Calle R., Pilleron J.P., Schlienger P., and Vilcoq J.R. Conservative management of operable breast cancer: ten years experience at the Foundation Curie. Cancer 42 (1978) 2045-2053
15. Nobler M.P., and Venet L. Twelve years' experience with irradiation as the primary treatment for breast cancer. Int J Radiat Oncol Biol Phys 7 (1981) 33-42
16. Arriagada R., Mouriesse H., Rezvani A., et al. Radiotherapy alone in breast cancer. Analysis of tumor and lymph node radiation doses and treatment-related complications. The experience of the Gustave-Roussy Institute and the Princess Margaret Hospital. Radiother Oncol 27 (1993) 1-6
17. Semiglazov V.F., Topuzov E.E., Bavli J.L., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5 (1994) 591-595
18. Scholl S.M., Fourquet A., Asselain B., et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A (1994) 645-652
19. Calitchi E., Otmezguine Y., Feuilhade F., et al. External irradiation prior to conservative surgery for breast cancer treatment. Int J Radiat Oncol Biol Phys 21 (1991) 325-329
20. Maher M., Campana F., Mosseri V., et al. Breast cancer in elderly women: a retrospective analysis of combined treatment with tamoxifen and once-weekly irradiation. Int J Radiat Oncol Biol Phys 31 (1995) 783-789
21. Courdi A., Ortholan C., Hannoun-Levi J.M., et al. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiother Oncol 79 (2006) 156-161
22. Paulsen G.H., Strickert T., Marthinsen A.B., and Lundgren S. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol 35 (1996) 1011-1019
23. Wazer D.E., Tercilla O.F., Lin P.S., and Schmidt-Ullrich R. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br J Radiol 62 (1989) 1079-1083
24. Sarkaria J.N., Miller E.M., Parker C.J., Jordan V.C., and Mulcahy R.T. 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res Treat 30 (1994) 159-165
25. Azria D., Larbouret C., Cunat S., et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 7 (2005) R156-R163
26. Kantorowitz D.A., Thompson H.J., and Furmanski P. Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma. Int J Radiat Oncol Biol Phys 26 (1993) 89-94
27. Pierce L.J., Hutchins L.F., Green S.R., et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23 (2005) 24-29
28. Harris E.E.R., Christensen V.J., Hwang W.-T., Fox K., and Solin L.J. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23 (2005) 11-16
29. Ahn P.H., Vu H.T., Lannin D., et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23 (2005) 17-23
30. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
31. Vincent-Salomon A., Rousseau A., Jouve M., et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 40 (2004) 1502-1508
32. ICRU: Report 50: Prescribing, recording, and reporting photon beam therapy. Washington DC: International Commission on Radiation Units and Measurements; 1993.
33. Campana F., Kirova Y.M., Rosenwald J.C., et al. Breast radiotherapy in the lateral decubitus position: a technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys 61 (2005) 1348-1354
34. Bollet M.A., Campana F., Kirova Y.M., et al. Breast radiotherapy in women with pectus excavatum (funnel chest): is the lateral decubitus technique an answer? A dosimetric study. Br J Radiol 79 (2006) 785-790
35. James K., Eisenhauer E., Christian M., et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91 (1999) 523-528
36. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
37. Bollet M.A., Sigal-Zafrani B., Gambotti L., et al. Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. Eur J Cancer 42 (2006) 2286-2295
38. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., and Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180 (1995) 297-306
39. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
40. Mauriac L., Durand M., Avril A., and Dilhuydy J.M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2 (1991) 347-354
41. Smith I.E., A'Hern R.P., Coombes G.A., et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15 (2004) 751-758
42. Bear H.D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 (2003) 4165-4174
43. Bollet M.A., Thibault F., Bouillon K., et al. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study. Int J Radiat Oncol Biol Phys (2007)
44. Chevallier B., Roche H., Olivier J.P., Chollet P., and Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16 (1993) 223-228
45. Dieras V., Fumoleau P., Romieu G., et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22 (2004) 4958-4965
46. Calitchi E., Kirova Y.M., Otmezguine Y., Feuilhade F., Piedbois Y., and Le Bourgeois J.P. Long-term results of neoadjuvant radiation therapy for breast cancer. Int J Cancer 96 (2001) 253-259
47. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
48. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
49. Dixon J.M., Renshaw L., Bellamy C., Stuart M., Hoctin-Boes G., and Miller W.R. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6 (2000) 2229-2235
50. Salmon R.J., Alran S., Malka I., et al. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment. Am J Clin Oncol 29 (2006) 385-388
51. Dixon J.M., Love C.D., Bellamy C.O., et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66 (2001) 191-199
52. Salmon R.J., Remvikos Y., Campana F., et al. Neo adjuvant tamoxifen in post menopausal patients with operable breast cancer. Eur J Surg Oncol 29 (2003) 831-834
53. Toillon R.A., Magne N., Laios I., et al. Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53. Int J Radiat Oncol Biol Phys 67 (2007) 1187-1200
54. Toillon R.A., Magne N., Laios I., et al. Interaction between estrogen receptor alpha, ionizing radiation and (anti-) estrogens in breast cancer cells. Breast Cancer Res Treat 93 (2005) 207-215
55. Steel G.G. Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 5 (1979) 1145-1150
56. Tubiana-Hulin M., Stevens D., Lasry S., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol (2006)
57. Pierga J.Y., Mouret E., Laurence V., et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer 39 (2003) 1089-1096
58. Mathieu M.C., Rouzier R., Llombart-Cussac A., et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40 (2004) 342-351
59. Durand J.C., Solalinde V., Mathieu G., et al. Conservative surgery after preoperative radiotherapy in the treatment of breast cancer. Indications and results. Bull Cancer 74 (1987) 641-646
60. Clough K.B., Lewis J.S., Couturaud B., Fitoussi A., Nos C., and Falcou M.C. Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Ann Surg 237 (2003) 26-34
61. Azria D., Gourgou S., Sozzi W.J., et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 91 (2004) 1251-1260
62. Koc M., Polat P., and Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol 64 (2002) 171-175
63. Bentzen S.M., Skoczylas J.Z., Overgaard M., and Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 88 (1996) 918-922
64. Huang E.Y., Wang C.J., Chen H.C., et al. Multivariate analysis of pulmonary fibrosis after electron beam irradiation for postmastectomy chest wall and regional lymphatics: evidence for non-dosimetric factors. Radiother Oncol 57 (2000) 91-96
65. Fowble B., Fein D.A., Hanlon A.L., et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 35 (1996) 669-677
66. Wazer D.E., Morr J., Erban J.K., Schmid C.H., Ruthazer R., and Schmidt-Ullrich R.K. The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. Cancer 80 (1997) 732-740